Please assess the completion status of the following clinical trial:

Trial Title: MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have histologically or cytologically confirmed invasive cancer of the breast~* Patients must have documented locally advanced/metastatic disease, defined by the investigator, which is not amenable to resection with curative intent.~* Patients must have HER2-positive breast cancer as defined by ASCO/CAP 2013 guidelines that is confirmed by a Sponsor-designated central laboratory~* Patients must have progressed on, or be intolerant to pertuzumab in the LABC/MBC setting or had disease recurrence within 12 months of pertuzumab treatment in the neoadjuvant or adjuvant setting.~* Patients must have progressed on, or be intolerant to ado-trastuzumab emtansine in the LABC/MBC setting~* Patients must have been previously treated with trastuzumab in any setting (which may have been previously administered with or without pertuzumab)~* ECOG Performance Status of 0 or 1~Exclusion Criteria:~* Patients who have previously been treated with doxorubicin, liposomal doxorubicin, epirubicin, mitoxantrone, or any other anthracycline derivative~* Subjects with central nervous system (CNS) metastases, unless they have been treated and are stable without symptoms for 4 weeks after completion of treatment and must be off steroids for at least 4 weeks prior to enrollment~* Patients with any class of New York Heart Association (NYHA) CHF or heart failure with preserved ejection fraction (HFPEF)~* Patients with a history of known coronary artery disease or a myocardial infarction within the last 12 months~* Patients with a known history of serious cardiac arrhythmias requiring treatment (exception: controlled atrial fibrillation, paroxysmal supraventricular tachycardia)~* Patients who previously discontinued trastuzumab due to unacceptable cardiac toxicity~* Patients with a history of LVEF decline to below 50% during or after prior trastuzumab/lapatinib or other HER2 directed therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MM-302 + trastuzumab (Type: EXPERIMENTAL): MM-302 + trastuzumab
- Chemotherapy of Physician's Choice plus trastuzumab (Type: ACTIVE_COMPARATOR): Chemotherapy limited to one of the following: Gemcitabine, Capecitabine or Vinorelbine

Based on this trial design, predict the completion outcome and termination type (if applicable).